Skip to content
Subscriber Only

WHO Should Buy Diabetes Drugs in Bulk for Poor, Novo CEO Says

The World Health Organization should buy low-cost diabetes treatments in bulk on behalf of the poorest countries to ensure they get the lowest price, the head of the world’s largest insulin maker said.

Most low- and middle-income countries pay too much for the medicines because they order relatively small amounts and few manufacturers bid for the tenders, Lars Rebien Soerensen, chief executive officer of Novo Nordisk A/S, said in an interview in London yesterday.